Malattie rare: miastenia grave, Celia (Argenx Italia) ‘importante innovazione farmacologica’

adnkronos

(Adnkronos) - “Siamo consapevoli del fatto che l'innovazione farmacologica oggi è sempre più importante, ma non è sufficiente, perché la gestione di malattie rare autoimmuni e la ricerca di soluzioni sempre più personalizzate per i pazienti devono assolutamente portare un cambio di paradigma”. Lo ha detto Fabrizio Celia, amministratore delegato di Argenx Italia, in occasione della presentazione dei risultati del primo studio in real world su scala globale che evidenzia l’impatto sociale e produttivo della miastenia grave su pazienti, familiari e caregiver. I risultati sono stati presentati a Milano all’incontro organizzato con la stampa ‘Miastenia grave. Una malattia rara che compromette le aspirazioni sociali e lavorative’.

Transcript

00:00Argenix is a Belgian company founded in 2008, which in a record time in the biotechnology field has become a pure research company,

00:13an integrated multinational that develops innovative solutions for rare autoimmune diseases.

00:18Our commitment in this sense, in addition to my serious stigma, will cover areas such as immune polyneuropathy, rather than myositis.

00:27Why do we undertake this commitment?

00:30On the one hand, these are therapeutic areas with a clinical need that is still unsatisfied and where pharmacological innovation has been lacking for several years.

00:38On the other hand, as we will see later in the press conference, these are the areas where the social impact of the disease is extremely high.

00:46Sometimes we make the methodological mistake of thinking that in these diseases the relationship is one-to-one between disease and disease,

00:52but the numbers that we are going to present today show that the social impact on caregivers is much higher.

01:01Hence our commitment to improve the quality of life not only of the patient, but also of the family.

01:06We have more innovative projects because we are aware that pharmacological innovation is increasingly important, but not sufficient.

01:15Why is this?

01:17Because on the one hand, the management of autoimmune diseases and on the other hand, the search for increasingly personalized solutions for patients must absolutely bring a change of paradigm.

01:29So we are working on three tools to try to create a health ecosystem that is increasingly connected.

01:36The first tool that we are putting in place is to work with models of artificial and generative intelligence

01:42that go alongside pharmacological innovation to try to improve the patient path and the care outcome.

01:47The second tool is to combine the know-how and expertise of the Italian Academy and the Italian Centers of Excellence

01:56with our know-how of the Immunology Innovation Program platform to try to create and develop, already in the preclinical phase,

02:03target molecules for certain markers and diseases.

02:08And the third tool is to work on access models, also inspiring the German Amnog, rather than the French SES-Percose,

02:16to try to make innovation usable for many patients who need innovative solutions.

Category

Transcript

Comments

Recommended